메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
나수영 (가톨릭대학교 의과대학 인천성모병원 내과) 최창환 (중앙대학교) Song Eun Mi (Department of Internal Medicine College of Medicine Ewha Womans University Seoul Korea.) 방기배 (단국대학교) 박상형 (울산대학교 의과대학 서울아산병원 소화기내과) 김은수 (경북대학교) 박재준 (연세대학교) 금보라 (고려대학교) 이창균 (경희대학교) 이보인 (가톨릭대학교) Ryoo Seung-Bum (Department of Surgery Seoul National University Hospital Seoul Korea.) Koh Seong-Joon (Department of Internal Medicine and Liver Research Institute Seoul National University College of Medicine Seoul Korea) Choi Miyoung (National Evidence-Based Healthcare Collaborating Agency Seoul Korea.) 김주성 (서울대학교)
저널정보
대한장연구학회 Intestinal research Intestinal research Vol.21 No.1
발행연도
2023.1
수록면
61 - 87 (27page)
DOI
10.5217/ir.2022.00007

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin α4β7 and anti-interleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0